Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Erin Gibbs
Ishares Nasdaq BiotechnologyIBBBUYJun 13, 2016
Erin GibbsUnknown
$264.43
Stock price when the opinion was issued
$172.20
As of Jun 18, 2026. Market Open.
E.T.F.'s
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
HOLD
He bought this, expecting biotech to break out, but it's been deeply disappointing. It hasn't worked yet.
Joe TerranovaOwned
E.T.F.'s
BUY
He likes biotech, focusing on longevity research. Better than owning a single biotech stock where you can lose 80% just on negative research findings. It's completely random--you have no idea what the outcome will be on these biotech products. Might as well own IBB and lessen risk.
Kevin O'LearyOwned
E.T.F.'s
DON'T BUY
IBB vs. XLV XLV has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.
E.T.F.'s
BUY ON WEAKNESS
BUY
Healthcare sector outlook The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.
E.T.F.'s
TOP PICK
Growth of biotech is expected to explode in a post-pandemic world. Longer term, aging population and growth of middle class are tailwinds. 27 bps expense ratio. Yield is 0.22%.
Stan WongOwned
E.T.F.'s
She likes Biotech’s. They are within the healthcare sector, and by far one of the more attractive industries. There is an enormous amount of double digit growth that we are still expecting from Biotech’s. They are trading rich, but that is because they are growing 2-3 times faster than the rest of the market. Sees this as a safe entry point.